TABLE. Number and percentage of infants immunized against respiratory syncytial virus through receipt of nirsevimab monoclonal antibody or maternal vaccination, by demographic characteristics — 33 states and District of Columbia,* October 2023–March 2024.
| Characteristic | No. (%) |
|
|---|---|---|
| Infants who received nirsevimab† | Pregnant women who received RSV vaccine§ | |
|
Total, no.
|
213,659
|
119,879
|
|
Infant’s age at nirsevimab receipt
| ||
| 0–3 days |
44,510 (20.8) |
— |
| 4–6 days |
36,818 (17.2) |
— |
| 7 days–<1 mo |
65,009 (30.4) |
— |
| 1 mo |
33,160 (15.5) |
— |
| 2–5 mos |
34,162 (16.0) |
— |
|
Mother’s age at RSV vaccine receipt, yrs
| ||
| 18–24 |
— |
13,105 (10.9) |
| 25–34 |
— |
70,921 (59.2) |
| 35–49 |
— |
35,853 (29.9) |
|
Immunization month and year
| ||
| Sept 2023 |
— |
501 (0.4) |
| Oct 2023 |
9,096 (4.3) |
10,235 (8.5) |
| Nov 2023 |
39,324 (18.4) |
27,866 (23.2) |
| Dec 2023 |
44,095 (20.6) |
37,938 (31.6) |
| Jan 2024 |
43,245 (20.2) |
43,339 (36.2) |
| Feb 2024 |
43,142 (20.2) |
— |
| Mar 2024 |
34,757 (16.3) |
— |
|
Vaccines for Children program eligibility
¶
| ||
| Eligible |
91,817 (43.0) |
— |
| Ineligible |
74,907 (35.1) |
— |
| Unknown |
46,935 (22.0) |
— |
|
Infant’s birth month and year
| ||
| Oct 2023 |
47,020 (22.0) |
— |
| Nov 2023 |
46,507 (21.8) |
— |
| Dec 2023 |
40,941 (19.2) |
— |
| Jan 2024 |
34,008 (15.9) |
— |
| Feb 2024 |
27,377 (12.8) |
— |
| Mar 2024 | 17,806 (8.3) | — |
Abbreviation: RSV = respiratory syncytial virus.
* Includes Alaska, Arizona, Arkansas, California, Connecticut, Delaware, Florida, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming.
† Includes infants born during October 1, 2023–March 31, 2024, who received at least 1 dose of nirsevimab during October 1, 2023–March 31, 2024.
§ Includes women (defined in the Immunization Information Systems as persons whose sex was female) who were aged 18–49 years at the time of RSV vaccination and received the vaccine (Abrysvo) during September 1, 2023–January 31, 2024. These women were presumed to be pregnant because RSV vaccination is only recommended for women in this age group if they are pregnant.
¶ The Vaccines for Children program provides vaccines at no cost to uninsured and underinsured children through enrolled public and private health care providers.